BC001 + sintilimab + oxaliplatin + capecitabine

**BC001 + sintilimab + oxaliplatin + capecitabine** is a combination regimen under clinical investigation, particularly for advanced or metastatic solid tumors including gastric and colorectal cancers. The regimen combines several active agents: - **BC001** is a fully human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2). It inhibits VEGF-mediated angiogenesis, thereby limiting tumor vascularization and growth. - **Sintilimab (Tyvyt, IBI308)** is a recombinant human monoclonal antibody against programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to enhance T-cell mediated anti-tumor immunity. - **Oxaliplatin** is a platinum-based chemotherapeutic that creates DNA crosslinks and inhibits DNA synthesis, leading to tumor cell apoptosis. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), an antimetabolite cytotoxic agent that inhibits thymidylate synthase and interferes with DNA synthesis. The combination of targeted anti-VEGFR2 therapy, immune checkpoint inhibition, and cytotoxic chemotherapy is being explored for potential synergistic efficacy in solid tumors, especially gastrointestinal cancers[1][2][3][4].

Other names

DaboshuCapeOx